España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Collins Stewart
UPDATE: Collins Stewart Lowers Target to $8 on Cbeyond
Collins Stewart: Level 3 Communications' Outlook Remains in Question
UPDATE: Collins Stewart Downgrades Cablevision
Collins Stewart: Level 3 Communications' Outlook Remains in Question
UPDATE: Collins Stewart Downgrades Cablevision
Collins Stewart Maintains Neutral, $2 PT on Savient Pharmaceuticals
UPDATE: Collins Stewart Reiterates Sell, $12 PT on Amylin Pharmaceuticals
Collins Stewart Maintains Neutral, $2 PT on Savient Pharmaceuticals
UPDATE: Collins Stewart Reiterates Sell, $12 PT on Amylin Pharmaceuticals
UPDATE: Collins Stewart Finds SBA Communications Very Attractive; Raises PT
UPDATE: Collins Stewart Downgrades Human Genome Sciences to Neutral
Read More...
Collins Stewart Recent News
UPDATE: Collins Stewart Raises Target to $70 on Digital Realty Trust
Collins Stewart Maintains Neutral, $11 PT on Cbeyond
UPDATE: Collins Stewart Downgrades Leap Wireless International to Neutral
UPDATE: Collins Stewart Raises Price Target on Equinix to $150
Collins Stewart: Incyte's Jakafi Knocks 4Q Sales Out of the Park
Collins Stewart: Masimo's '11 Ends Well and '12 Guidance May Prove Conservative
Collins Stewart: SunEdison Remains Key for MEMC Electronic Materials
UPDATE: Collins Stewart Raises Target to $50 on Rackspace Hosting
Collins Stewart: United Therapeutics Reiterates FY12/FY13 Revenue Guidance, Despite 4Q11 Miss
Collins Stewart: Palifosfamide P2 OS Data Bodes Well for P3
Collins Stewart Sees No Meaningful Catalysts on the Horizon for Rovi
Collins Stewart: 3 out of Last 4 Q's for NetApp Have Been Disappointing
UPDATE: Collins Stewart Raises Target to $95 on LinkedIn
UPDATE: Collins Stewart Downgrades First Solar to Neutral
Collins Stewart Maintains Lnkd at Buy, Raises PT from $86 to $95
Collins Stewart Downgrades First Solar from Buy to Neutral, Maintains PT at $40
UPDATE: Collins Stewart Upgrades Arris Group to Buy
Collins Stewart Maintains Urban Outfitters at Neutral, Lowers PT from $26 to $25
Collins Stewart Upgrades Arris Group from Hold to Buy, Raises PT to $15
Collins Stewart Maintains ON Semiconductor at Buy, Raises PT from $10 to $11
Collins Stewart Remains Neutral on Dolby's Stock Repurchase Announcement
Collins Stewart Says to Buy Perrigo on Weakness
UPDATE: Collins Stewart Downgrades Morgan Stanley to Hold